RE:Potential?The MD&A disclosures shed light on the market landscape, notably highlighting the serious issues of industry titans like GE and Bracco towards supply chain, drug safety and environmental sustainability. This narrative confirms Voyageur's position as a standout investment opportunity in my opinion, as frustrating as it has been to own shares in this company. As a domestic producer, Voyageur possesses a unique advantage in resilience against disruptions in global supply chains. In the event of a scenario like a global conflict disrupting traditional trade routes, Voyageur's localized operations offer a shield against such volatility. This strength not only mitigates risk but also positions Voyageur as a dependable asset within a potentially turbulent market. Furthermore, their carbon-based pharmaceuticals are poised to drive considerable value for investors. We need to see sales and this new barium product line launched. With that, I can not see the markets ignoring this company moving forward. There is too much instability in the world, and Big Pharma has confirmed that Voyageur is 100% the only company that is building a strategy to meet the needs of the healthcare industry. This company will potentially be bought in the future, there is a clear exit strategy being built by management.